Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Royal Bank of Canada from ...

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Analysts estimate that FX headwinds could impact financial results by approximately $20-25 million in the coming quarters. Bausch + Lomb's product portfolio, particularly its prescription Dry Eye ...

Though most of us experience dry eyes occasionally ... a variety of ophthalmological brands and working for Bausch & Lomb marketing contact lenses, surgical equipment, IOL's and general eyecare ...

A look at the biggest news and advancements in ophthalmology in 2024.

After hours: January 29 at 6:13:01 PM EST Loading Chart for BLCO ...

DelveInsight's Dry Eye Disease Market Insights report includes a comprehensive understanding of current treatment practices, ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.